Investigating Potential Claims involving Outlook Therapeutics
The White Law Group is investigating potential securities claims involving broker-dealers who may have unsuitably recommended Outlook Therapeutics to investors.
Outlook Therapeutics, Inc., (formerly known as Oncobiologics, Inc.) a clinical-stage biopharmaceutical company, reportedly engages in identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics.
Oncobiologics filed a form D to raise capital from investors in 2015. The total offering amount sold was purportedly $31,050,000.
According to a press release on Dec. 01, 2020 the company which has been working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced it has regained compliance with the minimum bid price for continued listing on the Nasdaq Capital Market, as the closing bid price of Outlook Therapeutics’ common stock had been at $1.00 or greater for 10 consecutive trading days.
Outlook’s shares have declined more than -80% since February 2019, according to MarketWatch.